Efficacy and Safety of Salvianolic Acid on AIS

Summary

Stroke has the characteristics of high morbidity, disability and fatality rate, which brings heavy spiritual and economic burdens to the family, society and the country. In my country, 33%-50% of ischemic strokes are attributed to intracranial atherosclerosis.

Studies have shown that oxidative stress, increased blood viscosity, and damage to vascular endothelial cells are important mechanisms for the development of cerebral infarction. Salvia miltiorrhiza is a commonly used traditional Chinese medicine in traditional medicine in my country. Salvia miltiorrhiza polyphenolic acid is the effective ingredient of salvia miltiorrhiza. It is the water-soluble active part of salvia miltiorrhiza. It can resist oxidation, anticoagulation, antiplatelet, cell protection, and expand blood vessels, thereby achieving protection Cardiovascular system.

The purpose of this study was to evaluate the effects and adverse effects of salvianolic acid on acute ischemic stroke onset within 72 hours, and to evaluate the improvement of patients' ischemic area perfusion and clinical function scores.

Conditions

• Stroke

Interventions

DRUG

Salvianolic Acid

salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days

DRUG

0.9% NaCl

0.9% NaCl

Sponsors & Collaborators

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Second Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Zhejiang University

  collaborator OTHER

• Ningbo No. 1 Hospital

  collaborator OTHER

• Zhejiang Hospital

  collaborator OTHER

• Zhejiang Provincial Tongde Hospital

  collaborator OTHER

• The First Affiliated Hospital of Zhejiang Chinese Medical University

  collaborator OTHER

• Xiaoshan People's Hospital

  collaborator OTHER

• Red Cross Hospital, Hangzhou, China

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-02-03

Primary Completion

2023-02-03

Completion

2023-02-03

Countries

• China

Study Locations